Yabin Cheng, Ph.D., Assistant Professor
Experience
Bachelor: Ocean University of China, Major in Pharmacy, 2000-2004
Master: Ocean University of China, Major in Pharmacology, 2004-2007
PhD: University of British Columbia (Canada), Major in Experimental Medicine, 2008-2014
Postdoc: University of British Columbia (Canada), School of Dermatology, 2014-2015
Research
Research interests include: cancer biology, biomarkers for cancer diagnosis, progression, prognosis and predictor for therapy treatment, novel cancer therapeutic target and drugs development, protein homeostasis. Since joined Xiamen University, Dr. Cheng has lead or participated in more than 14 national and provincial grant projects, published more than 38 research or review papers on top medical journals, including Molecular Cell, EMBO Journal, Cell Chemical Biology, Cell Reports, Journal of Investigative Dermatology and Oncogene. Dr. Cheng was awarded the overseas talent program of Fujian Province in 2018.
Team
Dr.Cheng has established a research team consisting of Master, PhD students and various collaborators from different areas, including molecular biology, drug chemistry, pharmaceutical metabolism and pharmacology.
Selected Publications (last 5 years):
1. Haoran Duan, Siqiong Zhang, Yoram Zarai, Rupert Ollinger, Yanmeng Wu, Li Sun, Cheng Hu, Yaohui He, Guiyou Tian, Roland Rad, Xiangquan Kong*, Yabin Cheng*, Tamir Tuller, Dieter Wolf*. eIF3 mRNA selectivity profiling reveals eIF3k as a cancer-relevant regulator of ribosome content. EMBO Journal. 2023 May 8;e112362. (Co-corresponding-authors，IF:14.012)
2. Cheng Hu, Weiming Lin, Kemeng Zhao, Guiyou Tian, Xiangquan Kong, Guangcheng Luo*, Dieter A Wolf*, Yabin Cheng*. NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinoma. iScience. 2023 April 3;26(4):106531. (Co-corresponding-authors，IF:6.107)
3. Shashi Jain, Cheng Hu, Jerome Kluza, Wei Ke, Guiyou Tian, Madalina Giurgiu, Andreas Bleilevens, Alexandre Rosa Capos, Adriana Charbono, Elmar Stickeler, Jochen Maurer, Elke Holinski-Feder, Arkadii Vaisburg, Matthias Bureik, Guangcheng Luo, Philioppe Marchetti, Yabin Cheng*, Dieter A Wolf*. Metabolic targeting of cancer by a ubiquinone uncompetitive inhibitor of mitochondrial complex I. Cell Chemical Biology. 2022 Mar 17;29(3):436-450.e15. (Co-corresponding-authors，IF:9.039)
4. Guiyou Tian, Hu Cheng, Yun Yun, Wensheng Yang, Wolfgang Dubiel, Yabin Cheng*, Dieter A Wolf*. Dual roles of HSP70 chaperone HSPA1 in quality control of nascent/newly synthesized proteins. EMBO Journal. 2021 May 19:e106183. (Co-corresponding-authors, IF:14.012)
5. Xue Zhang, Ming-Wan Su, Yabin Cheng, Magdalena Martinka, Gang Wang, Yuanshen Huang, Lingling Li, Youwen Zhou. Immunohistochemistry analysis reveals lysyl oxidase-like 3 as a novel prognostic marker for primary melanoma. Melanoma Research. 2021 Apr 1;31(2):173-177. (IF:3.199)
6. Jing Wang, Dawadschargal Dubiel, Yanmeng Wu, Yabin Cheng, Dieter A Wolf, Wolfgang Dubiel. CSN7B defines a variant Cop9 signalosome complex with distinct function in DNA damage response. Cell Reports. 2021 Jan 26;34(4):108662. (IF:9.995)
7. Yingying Lin#, Fajin Li#, Linlu Huang, Christine Polte, Haoran Duan, Jianhuo Fang, Li Sun, Xudong Xing, Guiyou Tian, Yabin Cheng*, Zoya Ignatova, Xuerui Yang*, Dieter A. Wolf*. eIF3 Associates with 80S ribosomes to promote translation elongation, mitochondrial homeostasis, and muscle health. Molecular Cell. 2020 Aug 20;79(4):575-587.e7. (Co-corresponding-authors, IF:19.328)
8. Dieter A. Wolf*, Yingying Lin, Haoran Duan, Yabin Cheng. eIF-three to tango: emerging function of translation initiation factor eIF3 in protein synthesis and disease. J Mol Cell Biol. 2020 Jul 3;12(6):403-409. (IF:8.185)
9. Xin Chen, Xiaosong Liu, Bin Deng, Magdalena Martinka, Youwen Zhou, Xiaopeng Lan*, YabinCheng*. Cytoplasmic Pin1 expression is increased in human cutaneous melanoma and predicts poor prognosis. Sci Rep. 2018 15;8(1):16867. (Co-corresponding-authors, IF:4.996)
Tel: +86-592-2881113
Email: chengyb@xmu.edu.cn
